Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To determine the antimyeloma effect of bortezomib after allogeneic transplantation for
patients with multiple myeloma.
Secondary Objective
1. To determine the toxicity profile of bortezomib in patients with multiple myeloma
undergoing allogeneic progenitor cell transplantation.